Skin Gene Expression Profiles in Systemic Sclerosis: From Clinical Stratification to Precision Medicine
暂无分享,去创建一个
[1] J. D. de Vries-Bouwstra,et al. Cutaneous Manifestations, Clinical Characteristics, and Prognosis of Patients With Systemic Sclerosis Sine Scleroderma: Data From the International EUSTAR Database. , 2023, JAMA dermatology.
[2] John Nguyen,et al. Tripterygium wilfordii derivative celastrol, a YAP inhibitor, has antifibrotic effects in systemic sclerosis , 2023, Annals of the Rheumatic Diseases.
[3] A. Yoshizaki,et al. Impact of guselkumab on three cases of SSc accompanying psoriasis. , 2023, Rheumatology.
[4] R. Lafyatis,et al. Single-Cell Transcriptome Analysis Identifies Subclusters with Inflammatory Fibroblast Responses in Localized Scleroderma , 2023, International journal of molecular sciences.
[5] H. Sumida,et al. Interleukin-17 pathway inhibition with brodalumab in early systemic sclerosis: analysis of a single-arm, open-label, phase 1 trial. , 2023, Journal of the American Academy of Dermatology.
[6] D. Rimar,et al. Differentially expressed genes in systemic sclerosis: Towards predictive medicine with new molecular tools for clinicians. , 2023, Autoimmunity reviews.
[7] M. Boubaya,et al. Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort. , 2022, The Lancet. Rheumatology.
[8] L. Tsoi,et al. Tofacitinib blocks IFN-regulated biomarker genes in skin fibroblasts and keratinocytes in a systemic sclerosis trial , 2022, JCI insight.
[9] J. Guthridge,et al. The promise of precision medicine in rheumatology , 2022, Nature Medicine.
[10] Tammara A. Wood,et al. A Genomic Meta-Analysis of Clinical Variables and Their Association with Intrinsic Molecular Subsets in Systemic Sclerosis. , 2022, Rheumatology.
[11] P. Lipsky,et al. Machine learning reveals distinct gene signature profiles in lesional and nonlesional regions of inflammatory skin diseases , 2022, Science advances.
[12] S. Svegliati,et al. PDGF/PDGFR: A Possible Molecular Target in Scleroderma Fibrosis , 2022, International journal of molecular sciences.
[13] M. Mayes,et al. Large-scale analysis of longitudinal skin gene expression in systemic sclerosis reveals relationships of immune cell and fibroblast activity with skin thickness and a trend towards normalisation over time , 2021, Annals of the Rheumatic Diseases.
[14] L. Brogelli,et al. How do systemic sclerosis manifestations influence patients’ lives? Results from a survey on patients and caregivers , 2021, Current medical research and opinion.
[15] Wei Chen,et al. Transcriptomic Evaluation of Juvenile Localized Scleroderma Skin With Histologic and Clinical Correlation , 2021, Arthritis & rheumatology.
[16] Andrea C. Kakouri,et al. Fibrotic expression profile analysis reveals repurposed drugs with potential anti-fibrotic mode of action , 2021, PloS one.
[17] A. Barton,et al. Comprehensive analysis of the major histocompatibility complex in systemic sclerosis identifies differential HLA associations by clinical and serological subtypes , 2021, Annals of the Rheumatic Diseases.
[18] Tammara A. Wood,et al. Machine learning integration of scleroderma histology and gene expression identifies fibroblast polarisation as a hallmark of clinical severity and improvement , 2020, Annals of the Rheumatic Diseases.
[19] A. Iagnocco,et al. Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud's phenomenon and systemic sclerosis. , 2020, Autoimmunity reviews.
[20] Ami A. Shah,et al. Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile , 2019, Annals of the rheumatic diseases.
[21] Howard Y. Chang,et al. GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways , 2019, Nature Communications.
[22] Viktor Martyanov,et al. A Machine Learning Classifier for Assigning Individual Patients With Systemic Sclerosis to Intrinsic Molecular Subsets , 2019, Arthritis & rheumatology.
[23] S. Walsh,et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. , 2019, The New England journal of medicine.
[24] D. Furst,et al. OP0065 THE VERY EARLY DIAGNOSIS OF SYSTEMIC SCLEROSIS (VEDOSS) PROJECT: PREDICTORS TO DEVELOP DEFINITE DISEASE FROM AN INTERNATIONAL MULTICENTRE STUDY , 2019, Oral Presentations.
[25] G. Raghu,et al. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. , 2019, The New England journal of medicine.
[26] I. Tagkopoulos,et al. Compendium of skin molecular signatures identifies key pathological features associated with fibrosis in systemic sclerosis , 2019, Annals of the rheumatic diseases.
[27] W. Marut,et al. New insights into the genetics and epigenetics of systemic sclerosis , 2018, Nature Reviews Rheumatology.
[28] Dianxu Ren,et al. Novel classification for global gene signature model for predicting severity of systemic sclerosis , 2018, PloS one.
[29] Jaclyn N. Taroni,et al. Mycophenolate Mofetil Treatment of Systemic Sclerosis Reduces Myeloid Cell Numbers and Attenuates the Inflammatory Gene Signature in Skin. , 2018, The Journal of investigative dermatology.
[30] Haiyin Chen-Harris,et al. Skin Gene Expression Is Prognostic for the Trajectory of Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis , 2018, Arthritis & rheumatology.
[31] Z. Modrušan,et al. Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis , 2018, Annals of the rheumatic diseases.
[32] Tammara A. Wood,et al. Belimumab for the Treatment of Early Diffuse Systemic Sclerosis , 2018, Arthritis & rheumatology.
[33] C. Henke,et al. Extracellular matrix as a driver of progressive fibrosis. , 2018, The Journal of clinical investigation.
[34] T. Krieg,et al. Pathophysiological Mechanisms in Sclerosing Skin Diseases , 2017, Front. Med..
[35] Alex Kuo,et al. Integrated, multicohort analysis of systemic sclerosis identifies robust transcriptional signature of disease severity. , 2016, JCI insight.
[36] M. Balaan,et al. Acute Respiratory Distress Syndrome , 2016, Critical care nursing quarterly.
[37] M. Baron,et al. Late Nailfold Videocapillaroscopy Pattern Associated With Hand Calcinosis and Acro‐Osteolysis in Systemic Sclerosis , 2016, Arthritis care & research.
[38] A. Theocharis,et al. Extracellular matrix structure. , 2016, Advanced drug delivery reviews.
[39] Jeffrey T. Chang,et al. Dissecting the Heterogeneity of Skin Gene Expression Patterns in Systemic Sclerosis , 2015, Arthritis & rheumatology.
[40] Jane Worthington,et al. Influence of TYK2 in systemic sclerosis susceptibility: a new locus in the IL-12 pathway , 2015, Annals of the rheumatic diseases.
[41] Tammara A. Wood,et al. Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial , 2015, Arthritis Research & Therapy.
[42] M. Whitfield,et al. Gene expression profiling offers insights into the role of innate immune signaling in SSc , 2015, Seminars in Immunopathology.
[43] C. Chizzolini,et al. The role of the acquired immune response in systemic sclerosis , 2015, Seminars in Immunopathology.
[44] M. Whitfield,et al. Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. , 2015, The Journal of clinical investigation.
[45] Tammara A. Wood,et al. Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis , 2015, Arthritis Research & Therapy.
[46] Viktor Martyanov,et al. Systems Level Analysis of Systemic Sclerosis Shows a Network of Immune and Profibrotic Pathways Connected with Genetic Polymorphisms , 2015, PLoS Comput. Biol..
[47] Steven J. M. Jones,et al. Integrated Genomic Characterization of Papillary Thyroid Carcinoma , 2014, Cell.
[48] Oliver Distler,et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. , 2013, Arthritis and rheumatism.
[49] Tammara A. Wood,et al. Molecular Signatures in Skin Associated with Clinical Improvement During Mycophenolate Treatment in Systemic Sclerosis , 2013, The Journal of investigative dermatology.
[50] M. Mayes,et al. Genetics of scleroderma: implications for personalized medicine? , 2013, BMC Medicine.
[51] K. Lipson,et al. CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis , 2012, Fibrogenesis & tissue repair.
[52] O. Distler,et al. Molecular targets for therapy in systemic sclerosis , 2012, Fibrogenesis & tissue repair.
[53] S. Pendergrass,et al. Intrinsic gene expression subsets of diffuse cutaneous systemic sclerosis are stable in serial skin biopsies , 2012, The Journal of investigative dermatology.
[54] Simon M. Lin,et al. Egr-1 Induces a Profibrotic Injury/Repair Gene Program Associated with Systemic Sclerosis , 2011, PloS one.
[55] Teresa M. Przytycka,et al. Identifying Causal Genes and Dysregulated Pathways in Complex Diseases , 2011, PLoS Comput. Biol..
[56] Howard Y. Chang,et al. Molecular framework for response to imatinib mesylate in systemic sclerosis. , 2009, Arthritis and rheumatism.
[57] S. Pendergrass,et al. Correction: Molecular Subsets in the Gene Expression Signatures of Scleroderma Skin , 2008, PLoS ONE.
[58] F. Verrecchia,et al. Transforming growth factor-β and fibrosis , 2007 .
[59] T. Krieg,et al. Skin disease: a cardinal feature of systemic sclerosis. , 2006, Rheumatology.
[60] David Botstein,et al. Systemic and cell type-specific gene expression patterns in scleroderma skin , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[61] C. Denton,et al. Atlas of Ulcers in Systemic Sclerosis , 2019, Springer International Publishing.
[62] J. Rosenbloom,et al. Human Fibrotic Diseases: Current Challenges in Fibrosis Research. , 2017, Methods in molecular biology.
[63] G. Riemekasten,et al. [Management of digital ulcers in patients with systemic sclerosis]. , 2012, Deutsche medizinische Wochenschrift.